Open Access

Acute kidney injury in patients with SARS-CoV-2 infection



Adrien Joseph¹, Lara Zafrani^{1,3*}, Asma Mabrouki¹, Elie Azoulay^{1,2} and Michael Darmon^{1,2}

Abstract

Background: Acute Kidney Injury (AKI) is a frequent complication of severe SARS-CoV-2 infection. Multiple mechanisms are involved in COVID-19-associated AKI, from direct viral infection and secondary inflammation to complement activation and microthrombosis. However, data are limited in critically-ill patients. In this study, we sought to describe the prevalence, risk factors and prognostic impact of AKI in this setting.

Methods: Retrospective monocenter study including adult patients with laboratory confirmed SARS-CoV-2 infection admitted to the ICU of our university Hospital. AKI was defined according to both urinary output and creatinine KDIGO criteria.

Results: Overall, 100 COVID-19 patients were admitted. AKI occurred in 81 patients (81%), including 44, 10 and 27 patients with AKI stage 1, 2 and 3 respectively. The severity of AKI was associated with mortality at day 28 (p = 0.013). Before adjustment, the third fraction of complement (C3), interleukin-6 (IL-6) and ferritin levels were higher in AKI patients. After adjustment for confounders, both severity (modified SOFA score per point) and AKI were associated with outcome. When forced in the final model, C3 (OR per log 0.25; 95% CI 0.01–4.66), IL-6 (OR per log 0.83; 95% CI 0.51–1.34), or ferritin (OR per log 1.63; 95% CI 0.84–3.32) were not associated with AKI and did not change the model.

Conclusion: In conclusion, we did not find any association between complement activation or inflammatory markers and AKI. Proportion of patients with AKI during severe SARS-CoV-2 infection is higher than previously reported and associated with outcome.

Keywords: Acute kidney injury, COVID-19, Complement system proteins, Interleukin-6, Outcome, Intensive care units

Background

Since December 2019, severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread worldwide, causing more than 6.6 million cases and 390 000 deaths [1]. This pandemic has put unprecedented pressure on healthcare systems and especially on intensive care units (ICUs).

Acute Kidney Injury (AKI) is a frequent complication of severe SARS-CoV-2 infection but data are scarce in ICUs. AKI has been previously reported with an average incidence of 11% (8–17%) overall, with highest ranges in

*Correspondence: lara.zafrani@aphp.fr

¹ Service de médecine Intensive et de réanimation médicale, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris University, 1 avenue Claude Vellefaux, 75010 Paris, France

Full list of author information is available at the end of the article

the critically ill (23%; 14–35%) [2–4]. Different applications of the Kidney Disease Improving Global Outcomes (KDIGO) criteria for AKI, in particular different methods to estimate missing baseline creatinine and handling urinary output, can cause important variations of estimated incidence [5, 6] and may contribute to the discrepancies among these studies.

Multiple mechanisms are involved in COVID-19-associated AKI, ranging from direct viral infection of the kidney and secondary inflammation to complement activation and microthrombosis [7]. In particular, severe COVID-19 is associated with uncontrolled systemic inflammatory response with high levels of IL-6 [8] that could potentially lead to intrarenal inflammation and increased vascular permeability and share several features with hyperferritinemic syndromes such as



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

macrophage activation syndrome [9]. Furthermore, unrestrained activation of complement leads to endothelial cell dysfunction and intravascular coagulation that could participate in COVID-19-associated AKI [10]. Both IL-6 [11] and complement [12] have been proposed as therapeutic targets and understanding their role in COVID-19-associated AKI is therefore a priority.

However, most of the studies performed to date gave little data regarding definition of AKI or influence of inflammation and complement markers on AKI.

In this study, we sought to describe the prevalence, risk factors and prognostic impact of AKI during COVID-19 in the ICU.

Methods

Study design and cohort

We conducted a retrospective monocenter study including adult patients with laboratory confirmed SARS-CoV-2 infection admitted to the ICU of our university Hospital. All adult patients (age \geq 18 years) who tested positive by polymerase chain reaction testing of a nasopharyngeal sample for COVID-19 and were hospitalized from March 1, 2020 to June 1, 2020 were eligible.

This study was approved by an institutional review board (French Intensive Care Society—CE SRLF n°20– 32). Need for informed consent was waived as regard to the study observational design and in accordance with the French law. This study was conducted in accordance with the principles of the Declaration of Helsinki.

Data collection, definitions and measurements

All data were obtained from medical records and patients' charts. Baseline patients' characteristics were collected, including demographics and comorbidities before ICU admission. The variables recorded regarding ICU admission and treatments were relative to clinical presentation, reason for ICU admission, diagnosis, therapies implemented and outcomes.

Blood sampling and routine biological testing were performed on the day of admission according to the standard laboratory protocols.

All samples were immediately centrifuged at 3000 rpm at 4 °C for 10 min, separated from the cells and stored at -80 °C until biochemical assays of complement proteins C3, C4 (nephelometry) and sC5B9 (ELISA), IL-6 (ELISA) were performed. The primary outcome was mortality at day 28.

Definition of AKI

AKI was defined according to both urinary output and serum creatinine KDIGO criteria [13] as follows: stage 1—increase in serum creatinine by 0.3 mg/dl within 48 h or a 1.5–1.9 times increase in serum creatinine from baseline or urinary output < 0.5 ml/kg/h for 6–12 h within 7 days; stage 2—2.9 times increase in serum creatinine or urinary output < 0.5 ml/kg/h for \ge 12 h within 7 days; stage 3—3 times or more increase in serum creatinine or to \ge 4.0 mg/dl or initiation of RRT or urinary output < 0.3 ml/kg/h for \ge 24 h or anuria for \ge 12 h within 7 days. Patients were stratified according to the highest AKI stage attained during the first 7 days of ICU stay.

Baseline creatinine was defined as the best value in the 3 preceding months or if unavailable as the lowest value during ICU stay or was back calculated based on a glomerular filtration rate of 60 mL/min/1.73m² with MDRD equation in patients without known chronic kidney disease. Chronic kidney disease (CKD) was defined according to the KDIGO definition.

Modified SOFA was defined as SOFA score [14] excluding the renal component.

Statistical analysis

Continuous variables were described as median (interquartile range [IQR]) and compared between groups using the non-parametric Wilcoxon rank-sum test. Categorical variables were described as frequency (percentages) and compared between groups using Fisher's exact test. Mortality was assessed using survival analysis.

Independent risk factors of day 28 mortality were assessed using Cox model. Conditional stepwise variable selection was performed with 0.2 as the critical *p*-value for entry into the model, and 0.1 as the *p*-value for removal. Interactions and correlations between the explanatory variables were carefully checked. Validity of proportional hazards assumption, influence of outliers, and linearity in relationship between the log hazard and the covariates were carefully checked.

Independent risk factors of AKI were assessed using logistic regression. Conditional backward stepwise variable selection was performed with 0.2 as the critical *p*-value for entry into the model, and 0.1 as the *p*-value for removal. Interactions and correlations between the explanatory variables were carefully checked. Influence of outliers, and linearity in relationship between the log hazard and the covariates were carefully checked. It was preplanned to force, one by one, in the final model inflammation biomarker, ferritin, complement pathway dosage and PEEP level at admission should these variable not be selected.

Kaplan–Meier graphs were used to express the probability of death from inclusion to day 28. Comparisons were performed using the log-rank test.

Overall, rate of missing data was 6.6% with rate of missing data among major outcome or covariates was < 5%. As regard to completeness of the dataset, no imputation of missing data was performed. Statistical analyses were performed with R statistical software, version 3.6.2 (available online at https://www.r-project.org/) and the 'Survival' package was used. A p value < 0.05 was considered significant.

Results

Patients' characteristics

Overall, 100 COVID-19 patients were admitted in our ICU between March and May 2020 and included in this study. Patients' characteristics are described in Table 1. Median age was 59 years [53–67] and 70 patients (70%) were of male gender. Only 15 patients (15%) had no underlying disease. Hypertension (n=56, 56%), diabetes (n=30, 30%) and chronic kidney disease (n=29, 29%) were the main comorbidities. Thirty-six patients were obese (n=21, 21%) or overweight (n=25, 25%) and 30 (30%) were treated with angiotensin converting enzyme inhibitors or angiotensin-receptor blockers. Median SOFA score [without the renal component] was 3 [2–7]. Fifty-six patients (55%) required mechanical ventilation and 51 (51%) vasopressor therapy.

Risk factors of AKI in COVID-19 patients

Rate of patients with missing baseline serum creatinine was 67% (n=67) and did not differ between AKI and patients without AKI (74 vs. 65% respectively; p=0.67).

AKI occurred in 81 patients (81%), including 44 patients, 10 patients, 27 patients with AKI stage 1, 2 and 3 respectively. Among patients with AKI, 33 (41%) met only urinary output KDIGO criteria, 28 (35%) met only creatinine criteria and 20 (25%) met both. Urinary output criteria alone was more frequently involved in diagnosis of milder stage of AKI (AKI stage 1 (n=20, 45%) and stage 2 (n=6, 60%) compared to 26% in stage 3 (n=7, p=0.007). Thirteen (13%) required renal replacement therapy during the first 7 days in ICU.

Before adjustment, C3 (p=0.01), IL-6 (p=0.03) and ferritin levels (p=0.03) were associated with AKI severity, whereas soluble C5b9 fraction was not different (p=0.42) (Fig. 1).

In a multivariate model incorporating baseline chronic kidney disease, only modified SOFA was significantly associated with the development of AKI (OR per point 1.29; 95% CI 1.04–1.70).

When forced in the final model, C3 (OR per log 0.25; 95% CI 0.01–4.66), IL-6 (OR per log 0.83; 95% CI 0.51–1.34), ferritin (OR per log 1.63; 95% CI 0.84–3.32), or PEEP level (OR per mmHg 1.04; 95% CI 0.91–1.22) were not associated with AKI and did not change the model.

However, after adjustment for modified SOFA and CKD, C3 value higher than median was significantly

associated with a lower risk for AKI stage 2 or 3, compared to no AKI or AKI stage 1 (OR 0.17 95% CI [0.05– 0.54], p = 0.004), while the association between AKI stage 2 or 3 and IL-6, Ferritin, sC5b9 and PEEP levels did not reach statistical significance (Additional file 1: Table S1 and Figure S1).

Outcome analysis

Twenty-nine (29%) patients had died by day 28, 28 (35%) patients with AKI and 1 (5%) patient without AKI (p = 0.02). More than half of the patients with AKI stage 2 (n = 5, 50%) and 3 (n = 15, 56%) died before day 28. The severity of AKI was associated with mortality at day 28 (p = 0.013) (Fig. 2 and Additional file 1: Figure S2).

Patients who died were older (66 versus 57 years, p=0.001), suffered more frequently from chronic kidney disease (52 versus 20%, p=0.003), had higher SOFA score (8 versus 2, p < 0.001), ferritin levels (1805 versus 1148 mg/L, p=0.004) and IL-6 levels (204 versus 103 ng/mL, p=0.02), and were less often immunocompetent (46 versus 18%, p=0.01). Neither comorbidities nor BMI were associated with death at day 28. Patients who died more often required mechanical ventilation (90 versus 41%, p < 0.001), vasopressors (90 versus 36%, p < 0.001) and renal replacement therapy (31 versus 6%, p=0.002).

After adjustment for confounders, both AKI and severity (modified SOFA score per point) were associated with survival (Table 2).

There was a similar trend towards poorer survival in patients with (n=33) and without (n=67) baseline serum creatinine (Additional file 1: Figure S3).

We also tested the interaction between missing baseline serum creatinine and reported results and did not find any significant interaction (Additional file 1: Table S2).

Treatments with lopinavir/ritonavir (n = 10), tocilizumab (n = 1), eculizumab (n = 2) or chloroquine (n = 3) were associated neither with mortality nor with the development of AKI.

Discussion

In this study, we describe the incidence of AKI in 100 COVID-19 patients admitted to the ICU, and the link between AKI, inflammation markers and complement levels. The main results of this case series are the higher than previously reported incidence of AKI and its lack of association with IL-6, ferritin or complement factors C3 and sC5B9. The importance of AKI in COVID-19 patients has been increasingly recognized. If initial reports from China reported rates of AKI as low as 2.9–8% in severe patients [2, 15, 16], incidences from later studies ranged between 15% [17] and 44% [18] in critically ill patients. Most reports lack a clear operational AKI definition [19–21], but even in studies that used

Table 1 Patients' characteristics according to AKI

n=100n=19n=19Apr (war)50 [53-67]50 [46-61]60 [50 (50)60 [50Absence of under (ying comorbicity15 (59)6 (29)9 (79)60 [60Chone Cobratturke Pulmonary Disease2 (28)002 (80)100Hittory of typertension50 (58)8 (28)2 (24)6 (80)100Disclassi0 (209)8 (29)2 (24)0.010.01Internationary Disease20 (29)10 (18)2 (29)0.01Disclassi0 (209)10 (18)10 (19)0.01Beary faile20 (29)10 (18)2 (23)0.01Disclassi Inders (Kgrm?)20 (29)11 (18)2 (23)0.01Beary faile20 (29)11 (18)2 (23)0.01Beary Maximum (Kgrm?)20 (29)11 (18)12 (18)0.02Descing and overlassi5 (50)31 (68)13 (20)12Descing and overlassi(16)13 (68)13 (18)0.01Dise and AEE/ARB0 (20 (18)14 (18)100100Dise and AEE/ARB0 (20 (18)13 (18)10 (10)100Dise and AEE/ARB10 (19)10 (19)100100Dise and AEE/ARB10 (19)10 (19		Overall	No AKI n = 19	AKI n=81	<i>p</i> value
Approximation 59 (53-67) 54 (45-61) 60 (54-64) 0.05 Male gender 70 (70%) 11 (58%) 59 (73%) 0.32 Absence of indivity in comorbidity 15 (15%) 6 (22%) 9 (11%) 0.00 Chrono Obstructive Pulmonary Disease 2 (2%) 0 (0) 2 (9%) 1.00 Antma 8 (8%) 2 (11%) 6 (8%) 1.00 Interony of hypertension 56 (5%) 8 (42%) 48 (6%) 0.23 Diabetes 30 (3%) 3 (16%) 27 (3%) 0.29 Chronic Midney disease 29 (2%) 2 (11%) 27 (33%) 0.09 Chronic Midney disease 29 (2%) 2 (11%) 27 (33%) 0.09 Other disease 29 (2%) 2 (11%) 2 (23-31) 28 [24-31] 0.43 Obersympt 25 (5%) 3 (16%) 18 (22%) 0.09 0.09 Obers 21 (21%) 3 (16%) 13 (5%) 0.22 0.03 0.02 Start day of morthly 55 (5%) 6 (46%) 13 (6%)		n=100			
Male gender07.0%11.5%%59.73%%0.32Abance of underlying connationality15.15%6.23%0.11%0.68Chornic Obstructive Pulmonary Disease8.0%2.11%0.26%100Astima8.0%2.11%0.26%0.21%0.21Dispont Pulmonary Disease8.0%2.11%0.210.21Dispont Pulmonary Disease30.0%3.16%2.24%0.21Dispont Pulmonary Disease30.0%2.11%2.23%0.0%Dispont Pulmonary Disease20.0%2.11%2.23%0.0%Bady Mass Index (Kg/m ²)2.12%3.16%2.12%0.0%Dispont Pulmonary Disease2.02%2.11%2.23%0.0%Dispont Pulmonary Disease2.12%3.16%2.27%1.16%Dispont Pulmonary Disease2.12%3.16%2.27%2.23%Dispont Pulmonary Disease3.03%3.16%4.161%2.22%Dispont Pulmonary Disease3.03%3.16%0.041.00Disease Size Discont Disease3.03%3.16%0.040.01Disease Size Discont Disease3.03%3.16%0.040.01Disease Size Discont Disease3.16%3.16%0.040.01Disease Size Discont Disease3.16%3.16%0.040.01Disease Size Discont Disease3.16%3.16%0.040.01Disease Size Discont Disease3.16%3.16%0.040.01Disease Size Discont Disease3.16%3.	Age (year)	59 [53–67]	54 [45–61]	60 [54–68]	0.05
Abs-mer of underlying conorbidity15 (15%)6 (33%)9 (1%)0.06Chonic Obstructive Pulmonay Disease2 (2%)002 (3%)1.00Astma6 (8%)1006 (8%)1.00Hittory of hypertension56 (5%)4 (4%)4 (4%)0.25Diabetis0 (30)15 (1%)0.0115 (1%)0.01Chonic Idday disase0 (2%)11 (1%)2 (28%)0.01Body Massindex (Kg/m)28 (24-31)20 (2%)21 (1%)21 (2%)Oesing and anonympithe25 (25%)3 (16%)18 (22%)1.02Oesing and anonympith25 (25%)3 (16%)16 (1%)1.22Oesing and anonympithe25 (25%)3 (16%)16 (1%)0.22Obeling and anonympith25 (25%)3 (16%)16 (1%)0.22Descend and inflammatory diag (N)1 (1%)1001000.22SofA score3 (25%)6 (38-70)1 (1%)0.01Diagten entancia (unol/L)0 (24)1 (1%)0.010.01PEF at day 10 (01 (1%)0.010.010.01PEF at day 10 (01 (1%)0.010.010.01Diagtenerent therapy13 (15%)13 (15%)0.020.02Cat day 0 (ng/m1)13 (15%)13 (15%)13 (16%)0.02Cat day 0 (ng/m1)13 (15%)13 (15%)0.020.02Cat day 0 (ng/m1)13 (15%)13 (15%)13 (16%)0.02Cat day 0 (ng/m1)13 (15%)13	Malegender	70 (70%)	11 (58%)	59 (73%)	0.32
Chronic Obstructive Pulmonary Disease2 (2%)0 (0)2 (%)1.00Asthma8 (%)2 (1%)6 (%)0.02Diabetes30 (3%)3 (4%)4 (6%)0.23Diabetes30 (3%)3 (4%)2 (2%)0.23Immunocompromized30 (3%)4 (2%)2 (2%)0.08Chronic kidney disease29 (2%)2 (1%)2 (2%)0.08Obstructive (kg/m)2 (2%)2 (1%)2 (2%)0.08Obstructive (kg/m)2 (2%)3 (1%)2 (2%)0.08Obstructive (kg/m)2 (2%)3 (1%)1 (2%)0.02Obstructive (kg/m)2 (2%)3 (1%)1 (2%)0.02Obstructive (kg/m)2 (2%)3 (1%)0 (2%)0.02Sealine securi metationine (mo//)6 (50-93)6 (18-70)6 (50-03)0.02SofA score1 (1%)0.011 (1%)0.010.01Instare metationine (mo//)6 (50-93)6 (18-70)6 (19-01)0.01Instare metatine (mo//)10 (1%)1 (1%)0.010.010.01Instare metati	Absence of underlying comorbidity	15 (15%)	6 (32%)	9 (11%)	0.06
Achma8 (8%)2 (1 %)6 (8%)1.00History of ppertension56 (56%)8 (42%)40 (0%)0.21Immoncompromized26 (26%)4 (1%)27 (3%)0.02Immancompromized26 (26%)4 (1%)27 (3%)0.09Bear failure15 (15%)0 (0)27 (3%)0.09Body Maxindex (Kg/m²)26 (25%)2 (1%)27 (3%)0.09Body Maxindex (Kg/m²)25 (25%)3 (16%)2 (27%)1Obesity and averweight21 (21%)3 (16%)2 (27%)2Obesity and averweight21 (21%)3 (16%)4 (51%)2Obesity and averweight2 (25%)3 (16%)4 (51%)22Obesity and averweight2 (25%)3 (16%)4 (51%)0.02Descence area creatinic (uma/1)65 (50-93)6 (348-70)6 (50-00)0.22Baseline serve creatinic (uma/2)6 (50-93)6 (348-70)6 (36)0.04Nonscerodal anti-inflammatory drugs (%)1 (1%)0 (01 (1%)0.00Nonscerodal anti-inflammatory drugs (%)1 (1%)0 (00.041 (1%)0.04Rend englamemet therapy1 (3 (1%)1 (1%)0.041 (1%)0.04Rend englamemet therapy1 (3 (1%)1 (1%)0.041 (1%)0.04So (3 dx) (fig/m1)1 (3 (27-27))1 (3 (28-27))0 (3 (3 (28-27))0.02Cat dx (y (ng/m1)1 (3 (27-27))1 (28-27)0 (280.02So (3 dx) (fig/m1)1 (16/2-22)1	Chronic Obstructive Pulmonary Disease	2 (2%)	0 (0)	2 (3%)	1.00
History of hypertension56 (5%)8 (42%)48 (60%)0.25Dabelts30 (3%)31 (6%)22 (2%)0.21Dabelts30 (3%)10 (%)22 (2%)0.78Heart failure15 (1%)0.0015 (1%)0.09Chonic kidney disease20 (2%)21 (1%)28 (24-31)28 (24-31)28 (24-31)0.09Obesiy down down wight25 (2%)3 (16%)22 (27%)0.02Onewordight21 (2%)3 (16%)27 (3%)0.22Obesis down down wight30 (3%)3 (16%)27 (3%)0.22Soft Act ZMRB30 (3%)3 (16%)27 (3%)0.22Soft Act CMRB30 (3%)3 (16%)27 (3%)0.22Soft Act CMRB30 (3%)3 (16%)27 (3%)0.22Soft Act CMRB30 (3%)3 (16%)1.010.02Soft Act CMRB30 (3%)3 (16%)0.100.01Nasteroid anti-finarmatory drugs (%)1 (1%)0.011.010.01Invasion mechanical ventilation55 (5%)6 (32%)13 (6%)0.04Nasteroid Anti-finarmatory drugs (%)118 (6/-221)13 (6/-221)13 (6/-221)0.01Invasion mechanical ventilation13 (5%)0.0113 (6/-221)0.02Nasteroid Act My CMM13 (6/-221)13 (6/-221)13 (6/-221)0.02Soft Act dy Ong/mi13 (6/-221)13 (6/-221)13 (6/-221)0.02Cat day Ong/mi13 (6/-221)13 (6/-221)13 (6/-221)0.02<	Asthma	8 (8%)	2 (11%)	6 (8%)	1.00
Diabete30 (30%)3 (16%)27 (34%)0.21immuncompromized26 (24%)4 (21%)27 (34%)0.24Heart falture15 (15%)0.0015 (98%)0.09Chronk idding disease29 (29%)2 (13%)27 (33%)0.09Body Mass Index (Kgm ²)24 (24)1]0.480.080.08Body Mass Index (Kgm ²)25 (25%)3 (16%)22 (27%)0.37Obese21 (21%)3 (16%)41 (51%)0.22Other54 (54%)3 (16%)41 (51%)0.22Chronk use of ACE/ARB30 (30%)3 (16%)7 (33%)0.22Soles arum creatinine (umol/L)65 (50~93)63 (48~70)67 (50~100)0.22Sole Ascore4 (2-7)22 (2)312-710.003Nonstreoidal anti-Inflammatory drugs (%)1 (1%%)0.01000.04PEEP at day 10 (0-10)0 (0-41)8 (0-10)0.04PEEP at day 10 (0-11)10 (10,1)0.040.04PEEP at day 113 (51%)7 (3%)44 (53%)0.24It is day 0 (ng/mL)13 (173~1550)135 (122~493)13 (16%)0.44Sole Aday 0 (ng/mL)136 (173~1550)136 (122~51)0.350.94Astre Kidney injury-84 (157~11)455 (122~4)13 (16%)0.02Sole Aday 0 (ng/mL)138 (18%)0.0011 (12%)0.01Sole Aday 0 (ng/mL)138 (18%)0.0011 (12%)0.02Sole Aday 0 (ng/mL)63 (54-72)0.12	History of hypertension	56 (56%)	8 (42%)	48 (60%)	0.25
Immunocompronized26 (24%)4 (1%)2 (24%)0.78Heart falue15 (1%)0015 (1%)0.09Body Mass Index (Kg/m²)29 (294)26 (23-31)28 (24-31)0.48Desirg and overweight5 (25%)3 (16%)2 (24%)0.48Oenweight5 (25%)3 (16%)2 (23%)1Obese21 (1%)3 (16%)2 (23%)122Obese3 (16%)2 (1%)3 (16%)2 (3%)0.22Soft Actif ARB30 (30%)3 (48-70)6 (50-93)6 (48-70)6 (50-91)0.22Soft Actif ARB3 (38%)4 (27,7)2 (2,3)6 (50-91)0.000.000.00Insteroid anti-infarmatory drugs (%)1 (1%)0.001 (1%)0.040.04PEEP at al.1 (1%)0 (01 (1%)0.040.04Vaspressors5 (55%)6 (32%)4 (55%)0.24Lif at day (ng/mi.)13 (1%)13 (1%)14 (57%)0.022 at day (ng/mi.)13 (1%)13 (1%)14 (57%)0.022 at day (ng/mi.)13 (57%)13 (185-287)13 (186-287)0.022 at day (ng/mi.)13 (1%)12 (245-248)13 (100%)0.0112 (100%)2 at day (ng/mi.)13 (1%)12 (245-234)13 (160-532)0.022 at day (ng/mi.)13 (16%)12 (100%)10 (10%)10 (10%)2 at day (ng/mi.)10 (10%)10 (10%)10 (10%)10 (10%)2 at day (ng/mi.)16 (15%)10 (10%) <td>Diabetes</td> <td>30 (30%)</td> <td>3 (16%)</td> <td>27 (34%)</td> <td>0.21</td>	Diabetes	30 (30%)	3 (16%)	27 (34%)	0.21
Heart failure15 (15%)0 (0)15 (19%)0.09Chronic kothey disease29 (29%)2 (11%)28 (24-31)0.09Obese26 (2-3-31)28 (24-31)0.08Obese21 (21%)3 (16%)18 (22%)Ohren disease21 (21%)13 (08%)18 (27%)Ohren disease21 (21%)13 (08%)18 (21%)Ohren disease21 (21%)13 (08%)18 (21%)Ohren disease21 (21%)13 (08%)14 (13%)Ohren disease21 (21%)21 (31%)0.02Salenia esturi catantine (µmol/L)65 (50-93)61 (8-7)(61 (50-100)0.02Sofk Acore4 (27)21 (31%)0.01110%0.01Nonstencial ant-infammatory drugs (%)10 (19%)0.010.010.010.01Nonstencial ant-infammatory drugs (%)13 (13%)0.010.010.010.01Nonstencial ant-infammatory drugs (%)13 (13%)0.010.010.010.01Vasopersson15 (15%)0.0113 (16%)0.010.01Staf day (10g/mL)136 (172-15%)136 (126-51%)0.020.010.01Cata day 0 (ng/mL)136 (172-15%)136 (126-51%)0.020.010.01Staf day (10g/mL)14 (15%)122 (145-15%)131 (169-51%)0.010.01Staf day 0 (ng/mL)136 (172-15%)136 (169-51%)0.010.010.01Staf day 0 (ng/mL)14 (15%)122 (145-15%)0.020.010.010.	Immunocompromized	26 (26%)	4 (21%)	22 (28%)	0.78
Chronic kidney disease29 (29%)21 (1%)27 (3%)0.09Body Mass index (Kg/m²)28 (24-31)26 (23-31)28 (24-31)0.48Ocenveight21 (27%)31 (6%)21 (27%)77Ovenveight31 (6%)18 (22%)770.028Obese12 (1%)31 (6%)18 (25%)0.22Ohrnic use of ACE/ARB03 (3%)0.16%)41 (5%)0.22Baseline serum creatinie (µmol/L)65 (56-93)63 (48-70)67 (50-100)0.22SOFA score12-710.0330.0310%1.031.03Nonsteroidal anti-inflammatory drugs (%)10%61 (23%)0.041.040.04Real replacement therapy1010-010.040.040.040.040.040.04Real replacement therapy13 (1%)0.0513 (6%)-23713 (6%)-2370.060.04Gat day (0ng/mL)18 (67-237)13 (63-237)13 (16%)-2370.060.040.040.040.040.040.04Gat day (0ng/mL)18 (25%-418)31 (252-493)13 (264-619)0.020.010	Heart failure	15 (15%)	0 (0)	15 (19%)	0.09
Bedy Mass Index (Kg/m)28 [24-31]28 [24-31]28 [24-31]0.48Cbesign or overweight5<55%	Chronic kidney disease	29 (29%)	2 (11%)	27 (33%)	0.09
ObseignationUse of the set of	Body Mass Index (Kg/m ²)	28 [24–31]	26 [23-31]	28 [24–31]	0.48
Overweight 25 (25%) 3 (16%) 22 (27%) Obes 1 (1%) 3 (16%) 18 (22%) Other 54 (64%) 13 (68%) 41 (51%) Chonic use of ACE/ARB 30 (30%) 31 (48%) 27 (33%) 0.22 Baseline serum creatinine (µmol/L) 65 [50-93] 63 [48-70] 67 [50-100] 0.22 SOFA score 4 (2-7) 2 (2,3) 5 (2-7) 0.03 Invasive mechanical ventilation 55 (55%) 63 (32%) 49 (61%) 0.04 PEEP at day 1 0 (00 10 0.04 10 0.04 Vaspressors 51 (51%) 73 (7%) 44 (55%) 0.24 UE at day 0 (ng/mL) 138 (57-247) 136 (53-227) 131 (50-227) 0.93 C3 at day 0 (ng/mL) 348 (272-418) 31 [222-493] 346 (272-416) 0.06 C4 at day 0 (ng/mL) 373 [270-471] 455 (375-72) 0.32 0.22 Ferritin at day 0 (ng/mL) 373 [270-471] 453 [245-716] 333 [265-450] 0.22 Stabed day 0 (ng/mL) <	Obesity and overweight				0.37
Obse21(1%)3(16%)18 (2%)Other54(4%)16(8%)41 (51%)Chronic use of ACE/AR830(3%)3(16%)27 (33%)0.22Baseline serum creatinine (µmo//L)65 [50-3]63 [48-70]67 [50-10]0.22SOFA score4[2-7]2[2,3]5 [2-7]0.003Nonsteroidal anti-inflammatory drugs (%)11(%)0(011(%)1.00Invasive mechanical ventilation55 (5%)6 (32%)49 (6%)0.04PEEP at day10[0-10]0[0-4]8 [0-10]0.04Renal replacement therapy13 (13%)0 (013 (16%)0.14Vaspressors15 (5%)7 (37%)44 (5%)0.24Ids at day 0 (ng/ml)118 [67-287]13 [63-292]115 [69-287]0.06C4 at day 0 (ng/ml)138 [173-1550]1495 [1282-493]346 [272-416]0.66C5 (5%) at day 0 (ng/ml)37 [270-471]15 [282-493]346 [272-416]0.62C5 (5%) at day 0 (ng/ml)137 [270-471]15 [282-453]131 [1695-282]0.12Firitin at day 0 (ng/L)127 [263-224]118 [249-5154]131 [1695-282]0.22Firitin at day 0 (ng/L)127 [263-224]118 [249-5154]131 [1695-282]0.21Firiting at day 0 (ng/L)127 [263-224]118 [249-5154]131 [1695-282]0.21Stage 10 (0%)10 (0%)10 (0%)<	Overweight	25 (25%)	3 (16%)	22 (27%)	
Other54 (54%)13 (68%)41 (51%)Chronic use of ACE/ARB30 (30%)31 (48%)27 (33%)0.22Baseline serum creatinine (µmol/L)65 (50–93)31 (48~70)67 (50–100)0.23Nonsteroidal anti-inflammatory drugs (%)11%)0(0)10%)10%100Invasive mechanical ventilation55 (55%)63 (28%)49 (61%)0.04Renal replacement therapy13 (13%)0(0)13 (64%)0.04Renal replacement therapy13 (13%)136 (63–292)13 (69–287)0.86C3 at day 0 (ng/mL)136 (172–273)136 (122, 1630)136 (10–1543)0.66C3 at day 0 (ng/mL)137 (276–471)425 (137–516)136 (26–450)0.22C3 at day 0 (ng/mL)137 (264–234)113 (149–1548)131 (69–3232)0.21Firtin at day 0 (g/L)127 (636–234)1132 (149–1548)131 (169–322)0.01Acute kidney injury -161 (16%)10(10%)0(0)No AKI19 (19%)19 (10%)0(110.12%)0.01Stage 110 (16%)10 (10%)10.12%)	Obese	21 (21%)	3 (16%)	18 (22%)	
Chronic use of ACE/ARB30 (30%)3 (16%)27 (33%)0.22Baseline serum creatinine (µmol/L)65 [50–93]61 (48–70)67 (50–100)0.22SOFA score4 (2–7)2 (2, 3)5 [2–7]0.00Invasive mechanical ventilation55 (55%)6 (32%)49 (61%)0.04Invasive mechanical ventilation55 (55%)6 (32%)49 (61%)0.04PEF at day 10 (0–100 (0–4)8 [0–10]0.04Renal replacement therapy31 (13%)0 (031 (66%)0.24Usa op (ng/mL)138 (67–287)136 (63–292)13 (69–287)0.96C3 at day 0 (ng/mL)305 (17.7–1550)136 (128–1584)36 (26–560)0.22C4 day 0 (ng/mL)37 (270–471)425 (137–516)36 (26–560)0.22Erritin at day 0 (ng/L)127 (636–2234)118 (249–1584)1311 (695–2322)0.12Elbichogen at day 0 (ng/L)81 (81%)0(031 (68%)<0001	Other	54 (54%)	13 (68%)	41 (51%)	
Baseline serum creatinine (µmol/L)65 [50-93]63 [48-70]67 [50-100]0.22SDFA score4 [2-7]2, 3]52-710.003Nonsteroidal anti-inflammatory drugs (%)1 (1%)0.001 (1%)0.00Invasive mechanical ventilation55 (55%)62 (32%)49 (61%)0.04PEEP at day 10 (0-10)0 (0-4]8 (0-10)0.04Vascoressors13 (13%)0 (0)13 (16%)0.14Vascoressors51 (51%)7 (37%)45 (55%)0.05L6 at day 0 (ng/mL)136 (57-287)136 (53-292)113 (59-287)0.98C3 at day 0 (ng/mL)305 (1173-1550)145 (128, 1630)1260 (1160-1543)0.06C4 at day 0 (ng/mL)63 (58-232)118 (2495-158)38 (272-416)0.69SC5b9 at day 0 (ng/mL)81 (81%)216 (14-7)767 (58-7)80.94Acute kidney injury-81 (81%)0 (0)11 (195-232)0.12Fibrinogen at day 0 (ng/L)81 (81%)0 (0)44 (54%)<000	Chronic use of ACE/ARB	30 (30%)	3 (16%)	27 (33%)	0.22
SOFA score 4 [2-7] 2 [2, 3] 5 [2-7] 0.003 Nonsteroidal anti-inflammatory drugs (%) 1 (1%) 0 (0) 1 (1%) 1.00 Invasive mechanical ventilation 55 (55%) 6 (32%) 49 (61%) 0.04 PEP at dy 1 0 (0-10] 0 (0-4) 8 (0-10) 0.04 Renal replacement therapy 13 (13%) 0 (0) 13 (16%) 0.14 Vasopressors 51 (51%) 7 (37%) 44 (55%) 0.24 L6 at day 0 (ng/mL) 136 (57-287) 136 (63-292) 113 (69-287) 0.98 C3 at day 0 (ng/mL) 348 [275-418] 351 [282, 1630] 1260 [1160-1543] 0.06 C4 at day 0 (ng/mL) 373 [270-471] 425 [317-516] 63 [266-450] 0.22 Ferritin at day 0 (mg/L) 68 [58-78] 7 [58-78] 0.94 Acute kidney injury- 81 (81%) 0(0) 61 [264%] <0001	Baseline serum creatinine (µmol/L)	65 [50–93]	63 [48–70]	67 [50-100]	0.22
Nonsteroidal anti-inflammatory drugs (%)1 (%)0 (%)1 (%)1.0%Invasive mechanical ventilation55 (55%)6 (32%)49 (61%)0.04PEEP ad y10 (0-10)0 (0-4)8 (0-10)0.04Renal replacement therapy13 (13%)0 (0)31 (16%)0.24Usa dop 0 (ng/mL)118 (67-287)136 (63-292)113 (69-287)0.98C3 at dop 0 (ng/mL)1305 (1173-1550)1495 (1285, 1630)1260 (1160-1543)0.06C4 at dop 0 (ng/mL)348 (275-418)351 (284-913)348 (272-416)0.69SC5D at dop 0 (ng/mL)1272 (636-2234)1182 (495-1584)311 (695-2322)0.12Firitin at dop 0 (ng/L)6.8 (5.8 - 7.8)0.018100%<0.00	SOFA score	4 [2-7]	2 [2, 3]	5 [2-7]	0.003
Invasive mechanical ventilation 55 (55%) 6 (32%) 49 (61%) 0.04 PEEP at day 1 0 [0-10] 0 [0-4] 8 [0-10] 0.04 Renal replacement therapy 13 (13%) 0 (0) 13 (16%) 0.14 Vasopressors 51 (51%) 7 (37%) 44 (55%) 0.24 It da day 0 (ng/mL) 118 (67-287] 13 (65-292) 113 (69-287) 0.98 C3 at day 0 (ng/mL) 1305 (1173-1550) 1495 [1285, 1630) 1260 (1160-1543) 0.66 C4 at day 0 (ng/mL) 348 [275-418] 351 [282-493] 348 [272-416] 0.69 sC5D9 at day 0 (ng/L) 127 [263-2224] 112 [495-1584] 131 [169-2322] 0.12 Fibrinogen at day 0 (g/L) 68 [5.8-7.8] 7.2 [5.4-7.7] 67 [5.8-7.8] 0.94 Acute (idney injury - 81 (81%) 0 (0) 81 (100%) <0001	Nonsteroidal anti-inflammatory drugs (%)	1 (1%)	0 (0)	1 (1%)	1.00
PEE at day 10 [0-10]0 [0-4]8 [0-10]0.04Renal replacement therapy13 (13%)0 (0)13 (16%)0.14Vasopressors5 (15%)7 (37%)44 (55%)0.24IL6 at day 0 (ng/mL)118 [67-287]136 [63-292]113 [69-287]0.06C3 at day 0 (ng/mL)305 [1173-1550]1495 [1285, 163)348 (27-416]0.69C4 at day 0 (ng/mL)373 [270-471]425 [317-516]363 [266-450]0.22Ferritin at day 0 (ng/L)1272 [636-2234]1182 [495-1584]131 [695-322]0.12Fibrinogen at day 0 (g/L)68 [5.8-7.8]0.00<001	Invasive mechanical ventilation	55 (55%)	6 (32%)	49 (61%)	0.04
Renal replacement therapy 13 (13%) 0 (0) 13 (16%) 0.14 Vasopressors 51 (51%) 7 (37%) 44 (55%) 0.24 Ll6 at day 0 (ng/mL) 118 [67–287] 136 [63–292] 113 [69–287] 0.98 C3 at day 0 (ng/mL) 1305 [173–1550] 1495 [1282-493] 348 [272–416] 0.06 C4 at day 0 (ng/mL) 373 [270–471] 425 [317–516] 0.63 [266–450] 0.22 Ferritin at day 0 (ng/L) 1272 [636–2234] 118 [495–1584] 311 [695–322] 0.12 Fibrinogen at day 0 (ng/L) 6.8 [5.8–7.8] 7.2 [5.4–7.7] 6.7 [5.8–7.8] 0.90 Acute kidney injury- 81 (81%) 0.00 81 (100%) <0.01	PEEP at day 1	0 [0-10]	0 [0-4]	8 [0-10]	0.04
Nasopressors 51 (51%) 7 (37%) 44 (55%) 0.24 LL6 at day 0 (ng/mL) 118 (67–287] 136 (63–292] 113 (69–287] 0.98 C3 at day 0 (ng/mL) 1305 (173–1550] 1495 (1285, 1630) 1260 (1160–1543) 0.06 C4 at day 0 (ng/mL) 348 (275–418] 51 (282–493) 348 (272–416) 0.06 C5 b9 at day 0 (ng/mL) 373 (270–471) 425 (317–516) 63 (266–450) 0.22 Fortrin at day 0 (ng/L) 6.8 (5.8–7.8] 1182 (495–1584) 1311 (695–2322) 0.12 Fortrin at day 0 (ng/L) 6.8 (5.8–7.8] 0.00 81 (100%) <0.00	Renal replacement therapy	13 (13%)	0 (0)	13 (16%)	0.14
LL à rday 0 (ng/mL)118 (67–287)136 (63–292)113 (69–287)0,98C3 at day 0 (ng/mL)1305 (1173–1550)1495 (1285, 1630)1260 (1160–1543)0,66C4 at day 0 (ng/mL)348 (275–418)351 [282–493]348 (272–416)0,22SC5b 9 at day 0 (ng/mL)1272 (54–2234)128 (249–156)363 (266–450)0,22Ferrita rd ay 0 (ng/L)1272 (56–2234)118 (495–1584)131 (695–2322)0,12Fibrinogen at day 0 (g/L)8 (85.8–7.8)0,216.7 (58–7.8)0,94Actus kidney injury -8 (85.8–7.8)0,206.7 (58–7.8)0,94KOLGO Starge19 (19%)0 (081 (100%)0,00KOLGO Starge10 (19%)0 (010 (12%)0,00KOLGO Starge20 (27%)0 (026 (35%)0,01Stage 30 (028 (25%)0 (028 (35%)0,01Carciner furfilded28 (28%)0 (0)33 (41%)1Creationic criteria alone28 (28%)0 (0)28 (25%)0,02Olgura alone30 (33%)0 (0)33 (41%)10,02Spectre triteria alone20 (20%)10 (0%)0,020,02Spectre triteria alone20 (29%)10 (10%)0,021None19 (19%)19 (10%)0,020,020,02Spectre triteria alone3 (3%)0,023 (41%)1Spectre triteria alone20 (20%)10 (20%)11Spectre triteria alone20 (20%)10 (20%)1<	Vasopressors	51 (51%)	7 (37%)	44 (55%)	0.24
C3 at a y 0 (ng/mL) 1305 [1173–1550] 1495 [1285, 1630] 1260 [1160–1543] 0.06 C4 at day 0 (ng/mL) 348 [275–418] 351 [282–493] 348 [272–416] 0.69 sC5b9 at day 0 (ng/mL) 373 [270–471] 425 [317–516] 363 [266–450] 0.22 Ferritin at day 0 (mg/L) 1272 [636–2234] 1182 [495–1584] 1311 [695–2322] 0.12 Fibrinogen at day 0 (g/L) 68 [5.8–7.8] 72 [5.4–7.7] 67 [5.8–7.8] 0.94 Acute kidney injury - 81 (81%) 0 (0 81 (100%) <0.001	IL6 at day 0 (ng/mL)	118 [67-287]	136 [63-292]	113 [69–287]	0.98
C4 at ay 0 (ng/mL) 348 [275-418] 351 [282-493] 348 [272-416] 0.69 sC5b9 at day 0 (ng/mL) 373 [270-471] 425 [317-516] 363 [266-450] 0.22 Ferritin at day 0 (ng/L) 1272 [636-2234] 1182 [495-1584] 1311 [695-2322] 0.12 Fibrinogen at day 0 (g/L) 6.8 [5.8-7.8] 7.2 [5.4-7.7] 6.7 [5.8-7.8] 0.94 Acute kidney injury - 81 (81%) 0 (0 81 (100%) <0.001	C3 at day 0 (ng/mL)	1305 [1173–1550]	1495 [1285, 1630]	1260 [1160–1543]	0.06
Sb9 at ayo (ng/mL) 373 [270-471] 425 [317-516] 363 [266-450] 0.22 Ferritin at day 0 (ng/L) 1272 [636-2234] 1182 [495-1584] 1311 [695-2322] 0.12 Fibrinogen at day 0 (g/L) 6.8 [5.8-7.8] 7.2 [5.4-7.7] 6.7 [5.8-7.8] 0.94 Acute kidney injury - 81 (81%) 0 (0 81 (100%) <0.01	C4 at day 0 (ng/mL)	348 [275–418]	351 [282–493]	348 [272–416]	0.69
Ferritin at day 0 (mg/L) 1272 [636–2234] 1182 [495–1584] 1311 [695–2322] 0.12 Fibrinogen at day 0 (g/L) 6.8 [5.8–7.8] 7.2 [5.4–7.7] 6.7 [5.8–7.8] 0.94 Acute kidney injury - 81 (81%) 0 (0) 81 (100%) <0.01	sC5b9 at day 0 (ng/mL)	373 [270–471]	425 [317–516]	363 [266-450]	0.22
Fibrinogen day 0 (g/L) 6.8 [5.8–7.8] 7.2 [5.4–7.7] 6.7 [5.8–7.8] 0.94 Acute kidney injury- 81 (81%) 0 (0) 81 (100%) <0.01	Ferritin at day 0 (mg/L)	1272 [636-2234]	1182 [495–1584]	1311 [695–2322]	0.12
Actue kidney injury 81 (81%) 0 (0) 81 (100%) <0.001	Fibrinogen at day 0 (g/L)	6.8 [5.8–7.8]	7.2 [5.4–7.7]	6.7 [5.8–7.8]	0.94
KDGO stage 19 (19%) 19 (10%) 0 (0) Stage 1 44 (44%) 0 (0) 44 (54%) Stage 2 10 (10%) 0 (0) 10 (12%) Stage 3 27 (27%) 0 (0) 27 (33%) KDIGO criteria fulfilled 27 (27%) 0 (0) 28 (35%) Creatinine criteria alone 28 (28%) 0 (0) 28 (35%) Oliguria alone 33 (33%) 0 (0) 33 (41%) Both criteria 20 (20%) 0 (0) 20 (25%) None 19 (19%) 19 (100%) 0 (0) 0.02 Day-28 mortality 29 (29%) 1(5%) 28 (35%) 0.02 Specific treatment during ICU stay 2(2%) 0 (0) 3 (4%) 0.02 Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) 0.02 Eculizumab 2(2%) 0 (0) 3 (4%) 0.02 1.01 Lopinavir/ritonavir 10 (10%) 0 (0) 1.012%) 1.01	Acute kidney injury -	81 (81%)	0 (0)	81 (100%)	< 0.001
No AKI 19 (19%) 19 (100%) 0 (0) Stage 1 44 (44%) 0 (0) 44 (54%) Stage 2 10 (10%) 0 (0) 10 (12%) Stage 3 7 (27%) 0 (0) 27 (33%) KDIGO criteria fulfilled 27 (27%) 0 (0) 28 (35%) Creatinine criteria alone 28 (28%) 0 (0) 28 (35%) Oliguria alone 33 (33%) 0 (0) 30 (41%) Both criteria 20 (20%) 0 (0) 20 (25%) None 19 (19%) 19 (100%) 0 (0) Day-28 mortality 29 (29%) 15%) 0.00 Specific treatment during ICU stay 2(2%) 0.01 0.02 Chloroquine or Hydroxychloroquine 3 (3%) 0.00 3 (4%) Eculizumab 2 (2%) 0.01 3 (4%) 0.02 Lopinavir/ritonavir 10 (10%) 0.00 10 (12%) 1.01	KDIGO stage				< 0.001
Stage 1 44 (44%) 0 (0) 44 (54%) Stage 2 10 (10%) 0 (0) 10 (12%) Stage 3 27 (27%) 0 (0) 27 (33%) <i>KDGO criteria fulfilled</i> 27 (33%) 0 (0) 28 (35%) Creatinine criteria alone 28 (28%) 0 (0) 28 (35%) 0 Oliguria alone 33 (33%) 0 (0) 33 (41%) 44 (40%) Stoch criteria 20 (20%) 0 (0) 20 (25%) 60%) None 19 (19%) 19 (10%) 0 (0) 0 Day-28 mortality 29 (29%) 10(%) 0.02 0.35%) 0.02 Specific treatment during ICU stay 3 (3%) 0.01 1.05%) 0.02 Chloroquine or Hydroxychloroquine 3 (3%) 0.02 0.02 0.02 Specific treatment during ICU stay 2 (2%) 0.01 3 (4%) 0.02 Lopinavit/ritonavir 0 (0) 0.01 1 (1%) 1 (1%)	No AKI	19 (19%)	19 (100%)	0 (0)	
Stage 2 10 (10%) 0 (0) 10 (12%) Stage 3 27 (27%) 0 (0) 27 (33%) KDIGO criteria fulfilled <	Stage 1	44 (44%)	0 (0)	44 (54%)	
Stage 3 27 (27%) 0 (0) 27 (33%) KDIGO criteria fulfilled <	Stage 2	10 (10%)	0 (0)	10 (12%)	
ADG o criteria fulfilled <	Stage 3	27 (27%)	0 (0)	27 (33%)	
Creatinine criteria alone 28 (28%) 0 (0) 28 (35%) Oliguria alone 33 (33%) 0 (0) 33 (41%) Both criteria 20 (20%) 0 (0) 20 (25%) None 19 (19%) 19 (100%) 0 (0) Day-28 mortality 29 (29%) 1 (5%) 28 (35%) 0.02 Specific treatment during ICU stay 29 (29%) 1 (5%) 3 (4%) 0.35 Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) 0.35 Lopinavir/ritonavir 2 (2%) 0 (0) 3 (4%) 1.5% Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) 1.5%	KDIGO criteria fulfilled				< 0.001
Oliguria alone 33 (33%) 0 (0) 33 (41%) Both criteria 20 (20%) 0 (0) 20 (25%) None 19 (19%) 19 (100%) 0 (0) Day-28 mortality 29 (29%) 1 (5%) 28 (35%) 0.02 Specific treatment during ICU stay 29 (29%) 1 (5%) 3 (4%) 0.35 Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) - 0.35 Eculizumab 2 (2%) 0 (0) 3 (4%) - - - Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) - - Tocilizumab 1 (1%) 0 (0) 1 (1%) - -	Creatinine criteria alone	28 (28%)	0 (0)	28 (35%)	
Both criteria 20 (20%) 0 (0) 20 (25%) None 19 (19%) 19 (100%) 0 (0) Day-28 mortality 29 (29%) 1 (5%) 28 (35%) 0.02 Specific treatment during ICU stay 29 (29%) 0 (0) 3 (4%) 0.35 Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) 1 Eculizumab 2 (2%) 0 (0) 2 (3%) 1 Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) 1 Tocilizumab 1 (1%) 0 (0) 1 (1%) 1	Oliguria alone	33 (33%)	0 (0)	33 (41%)	
None 19 (19%) 19 (100%) 0 (0) Day-28 mortality 29 (29%) 1.5%) 28 (35%) 0.02 Specific treatment during ICU stay 3 (3%) 0.00 3.4%) 0.35 Chloroquine or Hydroxychloroquine 3 (3%) 0.00 3.4%) 1 Eculizumab 2 (2%) 0.00 0.12%) 1 Lopinavir/ritonavir 10.10%) 0.00 1.1%) 1	Both criteria	20 (20%)	0 (0)	20 (25%)	
Day-28 mortality 29 (29%) 1 (5%) 28 (35%) 0.02 Specific treatment during ICU stay	None	19 (19%)	19 (100%)	0 (0)	
Specific treatment during ICU stay 0.35 Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) Eculizumab 2 (2%) 0 (0) 2 (3%) Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) Tocilizumab 1 (1%) 0 (0) 1 (1%)	Day-28 mortality	29 (29%)	1 (5%)	28 (35%)	0.02
Chloroquine or Hydroxychloroquine 3 (3%) 0 (0) 3 (4%) Eculizumab 2 (2%) 0 (0) 2 (3%) Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) Tocilizumab 1 (1%) 0 (0) 1 (1%)	Specific treatment during ICU stay				0.35
Eculizumab 2 (2%) 0 (0) 2 (3%) Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) Tocilizumab 1 (1%) 0 (0) 1 (1%)	Chloroquine or Hydroxychloroquine	3 (3%)	0 (0)	3 (4%)	
Lopinavir/ritonavir 10 (10%) 0 (0) 10 (12%) Tocilizumab 1 (1%) 0 (0) 1 (1%)	Eculizumab	2 (2%)	0 (0)	2 (3%)	
Tocilizumab 1 (1%) 0 (0) 1 (1%)	Lopinavir/ritonavir	10 (10%)	0 (0)	10 (12%)	
	Tocilizumab	1 (1%)	0 (0)	1 (1%)	
None 84 (84%) 19 (100%) 65 (80%)	None	84 (84%)	19 (100%)	65 (80%)	

Results are presented as median (interquartile) or n (%)

ACE angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers





KDIGO serum creatinine criteria, diuresis was inconsistently taken into account, and none of them reported AKI stages. Our study is the largest published to date reporting incidence of AKI specifically in critically ill patients.

With 81% of patients diagnosed with AKI, the rate of AKI in our study is much higher than previously reported.

Interestingly, one of the largest cohort from the United States reported a prevalence of AKI in COVID-19

	Estimate	95% CI	<i>p</i> value
Model 1 (survival censored at day 28)	Hazard ratio		
Modified SOFA score at admission (per point)	1.23	1.04–1.45	0.01
Acute Kidney Injury	3.08	1.12-8.45	0.03
Model 2 (acute kidney injury)	Odds ratio		
Chronic kidney disease	3.91	0.97–26.20	0.09
Modified SOFA score at admission (per point)	1.29	1.04-1.70	0.04

Table 2 Factors associated with survival censored at day 28 (Cox Model) and risk of AKI (logistic regression)

Model selection was performed according to forward variable selection conditioned on p value (critical entry p value <0.2, critical exit p value <0.1)

patients requiring mechanical ventilation of 80% [22], close to our finding of 90%.

One strength of our study is the rigorous use of KDIGO criteria, including urinary output. Furthermore, given that many patients will present with AKI without a reliable baseline serum creatinine on record, estimation of the latter is of tremendous importance. Several methods to estimate missing baseline creatinine can lead to variations in incidence of AKI up to 15% [6]. Using complete KDIGO definition we found a 80% incidence of AKI during the first 7 days of ICU stay and a 90% incidence in patients requiring mechanical ventilation.

We also tested the hypotheses that COVID-19-associated-AKI is linked to the elevation of cytokines induced by SARS-CoV-2 infection [23], complement dysregulation [12] induced by SARS-CoV-2 infection or mechanical ventilation settings. High levels of IL-6 have been associated with the development of severe disease [24, 25] and acute respiratory distress syndrome [8] during COVID-19 infection, but the role of inflammation markers in COVID-19-induced-AKI remains speculative [7]. The deleterious role of IL-6 has been demonstrated in different models of AKI, including ischemic AKI, nephrotoxin-induced AKI and sepsis-induced AKI [26, 27]. In our study, IL-6 and ferritin levels correlated with severity but were not independently associated with AKI. The complement system represents the first response of the host immune system. It participates in the development of AKI [28] and has also been suspected to play a role in AKI in the context of SARS-CoV-2 infection [10, 12]. Recent studies showed a strong immunohistochemical staining of complement cascade components in the lungs [29] and kidneys [30] of severe COVID-19 patients. However, even if C3 levels were associated with AKI severity in univariate analysis, the association did not persist when forced into a multivariate model, and soluble C5b9 showed no association with AKI. C3 level was only independently associated with AKI stage 2 and 3 compared to no AKI or AKI stage 1. Overall, our results do not support a role for complement dysregulation in COVID-19-induced-AKI, even though complement dysregulation may be involved in the most severe forms of AKI.

Although our study did not include extensive coagulation explorations [31], the lack of difference in fibrinogen levels in patients with AKI when compared to patients without AKI does not support the evidence of a role of hypercoagulability in COVID-19-induced-AKI, suggested by the presence of thrombi in glomerular loops described by others [32, 33]. Last, high levels of PEEP in COVID-19 patients [34, 35] have also been suggested as a potential factor for increased AKI in severe COVID-19 patients [36]. In our study, PEEP levels were not independently associated with the development of AKI, but the lack of statistical power and longitudinal data on PEEP levels does not allow for any definite conclusion.

Our study also has limitations. First, despite being the largest focusing on COVID-19-induced-AKI in the ICU, the limited number of patients can translate into a lack of statistical power. Nevertheless, rate of AKI and sample size allow confirming a high AKI incidence with a reasonable level of confidence (81%; 95% CI 72-89). In addition, the monocenter design may have limited external validity of our findings. The proportion of missing baseline serum creatinine value (67%) may also be an issue. Missing baseline creatinine value is a common problem in research focusing on AKI, and although most studies do not report the proportion of missing baseline values, rates as high as 85% are common [22]. We provide sensitivity analyses (Additional file 1: Figure S3 and Table S2) to show that back calculation of missing baseline creatinine values unlikely results in a significant bias. Last, lack of association between inflammation biomarker, IL-6 or complement component do not preclude participation of these mechanisms to AKI. They only underline that in this setting and when adjusted to severity, these factors have little influence on AKI rate. Additional studies, assessing levels of proteinuria and hematuria [22, 37], pathological findings and translational research are needed to further explore different mechanisms that may participate to AKI during severe SARS-CoV-2 infection.

In conclusion, we did not find any association between complement activation or inflammatory markers and AKI. Our study suggests a tremendously high incidence of AKI in our cohort of critically ill COVID-19 patients, along with an independent association between AKI and outcome. Because of its marked influence on outcome, AKI should be identified promptly during SARS-CoV-2 infection.

Supplementary information

Supplementary information accompanies this paper at https://doi. org/10.1186/s13613-020-00734-z.

Additional file 1: Figure S1. Boxplots depicting relationship between AKI stage 2 and 3 and C3 [ng/mL] (A), IL-6 [ng/mL] (B), sC5b9 [ng/mL] (C) and ferritin levels [mg/L] (D) levels, and predicted probabilities of severe AKI according to ferritin (E) and C3 (F) deciles (per log). Figure S2. Kaplan-Meier curve for day-28 survival in patients without AKI or with AKI stage 1 (n=63) compared to AKI stage 2 or 3 (n= 37). Figure S3. Kaplan-Meier curves for day-28 survival according to AKI (A and B) and AKI stages C and D) in patients with (n=33, B and D) and without (n= 67, A and C) baseline creatinine value. Table S1. Factors associated with risk of AKI stage 2 and 3, compared to no AKI or AKI stage 1, after adjustment for modified SOFA and chronic kidney disease (logistic regression). Table S2. Interaction between missing baseline serum creatinine and reported results.

Abbreviations

ACE2: Angiotensin-converting enzyme 2; AKI: Acute kidney injury; COVID-19: Coronavirus disease 2019; ICU: Intensive care unit; KDIGO: Kidney disease improving global outcome; PEEP: Positive end expiratory pressure; SARS-COV-2: Severe acute respiratory coronavirus 2.

Authors' contributions

MD, LZ and EA contributed to the study conception and design. AJ, MD, AM and LZ performed the data collection and the initial data analysis. AJ, LZ and MD prepared the first draft of the manuscript. All authors contributed to the data analysis and to the critical revision. All authors read and approved the final manuscript.

Ethics approval and competing interests

MD declares having received grant from MSD, speaker fees from MSD, Astelas and Gilead-Kite and having attended an advisory board for Gilead-Kite. LZ declares having received research grant from Jazz Pharmaceuticals. The other authors have no conflict of interest to declare.

Consent for publication

Not applicable.

Author details

¹ Service de médecine Intensive et de réanimation médicale, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris University, 1 avenue Claude Vellefaux, 75010 Paris, France. ² ECSTRA Team, UMR 1153, Center of Epidemiology and Biostatistics, INSERM, Université de Paris, Paris, France. ³ INSERM U976, Université de Paris, Paris, France.

Received: 11 June 2020 Accepted: 27 August 2020 Published online: 03 September 2020

References

1. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. https:// coronavirus.jhu.edu/map.html.

- Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://wwwnejm-org.proxy.insermbiblio.inist.fr/doi/10.1056/NEJMoa2002032.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497–506.
- Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46:1339.
- Koeze J, Keus F, Dieperink W, van der Horst ICC, Zijlstra JG, van Meurs M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. BMC Nephrol. 2017;18(1):70.
- Wiersema R, Jukarainen S, Eck RJ, Kaufmann T, Koeze J, Keus F, et al. Different applications of the KDIGO criteria for AKI lead to different incidences in critically ill patients: a post hoc analysis from the prospective observational SICS-II study. Crit Care Lond Engl. 2020;24(1):164.
- Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31:1380. https://jasn-asnjournals-org. proxy.insermbiblio.inist.fr/content/early/2020/05/04/ASN.2020040419
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China. JAMA Intern Med. 2020;18:1.
- Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020;5:102573.
- 10. Noris M, Benigni A, Remuzzi G. The case of Complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314.
- Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970–5.
- Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–4.
- Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
- Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix). Intensive Care Med. 1996;22(7):707–10.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
- Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343–8.
- Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;1(127):104364.
- Cao J, Hu X, Cheng W, Yu L, Tu W-J, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020;46(5):851–3.
- Xu S, Fu L, Fei J, Xiang H-X, Xiang Y, Tan Z-X, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv. 2020. https://doi. org/10.1101/2020.03.24.20042408.
- Luo X, Xia H, Yang W, Wang B, Guo T, Xiong J, et al. Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China. medRxiv. 2020. https://doi.org/10.1101/2020.03.19.20033175.
- 21. Hu L, Chen S, Fu Y, Gao Z, Long H, Wang J-M, et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa539.
- Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209.

https://www.kidney-international.org/article/S0085-2538(20)30532-9/ abstract

- 23. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl. 2020;395(10229):1033-4.
- 24. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
- 25. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature [Internet]. 2020 May 20 [cited 2020 Jun 6]; Available from: https://www.nature.com/articles/s4158 6-020-2355-0
- 26. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47(4):693-705.
- 27. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin Il receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605-10.
- 28. McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol. 2013;33(6):543-56.
- 29. Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Infect Dis. 2020. https://doi.org/10.1101/2020.03.29.20041 962
- 30. Diao B, Feng Z, Wang C, Wang H, Liu L, Wang C, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. 2020. https://doi. org/10.1101/2020.03.04.20031120.

- 31. Mortus JR, Manek SE, Brubaker LS, Loor M, Cruz MA, Trautner BW, et al. Thromboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill. JAMA Netw Open. 2020;3(6):e2011192-e20111922011192.
- 32. Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219. https://linkinghub.elsevier.com/retrieve/pii/ \$0085253820303690
- 33. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020:46:1089
- 34. Beloncle FM, Pavlovsky B, Desprez C, Fage N, Olivier P-Y, Asfar P, et al. Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome. Ann Intensive Care. 2020;10(1):55.
- COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099.
- is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38.

lished maps and institutional affiliations.

35. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al.

- 36. Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney cross-talk in the critically ill patient. Am J Respir Crit Care Med. 2016;194(4):402-14.
- 37. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in pub-

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at > springeropen.com